DOCSLIB.ORG

Treatment for Survival Prior to Death and Interpretation of Postmortem 'Toxicologic Findings

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment for Survival Prior to Death and Interpretation of Postmortem 'Toxicologic Findings If you have issues viewing or accessing this file contact us at NCJRS.gov. ------~--------- CHAPTER 4 Treatment for Survival Prior to Death and Interpretation of Postmortem 'Toxicologic Findings Eric G. Comstock, M.D, The protocol for postmortem examination not detectable at postmortem examination. in the medical examiner's or coroner's office Substances detected may be found to have should provide for a minimum toxicologic been administered medicinally and to have no examination in every death. Specimens to be causative role whatsoever. Concentrations of collected for t0xicologic evaluation should drugs for which tolerance develops may be so include: (a) gastric contents with notation of high as to be considered an unequivocal cause the total volume, (b) heart blood, (c) urine, of death in a pharmacologically naive individ­ (d) bile, and (e) selected tissues, such as liver, ual, while they may have played no role what­ lung, and kidney. soever in a chronic drug user. The minimum toxicologic examination The purpose of this discussion is to direct should provide for qualitative screening with attention to the circumstances which influ­ quantitation when the qualitative procedures ence the interpretation of toxicologic findings are positive. Minimum routine screening pro­ at postmortem examination. cedures should include a test for volatile organics and screening procedures for detec­ tion of a variety of groups of drugs. Circum­ CIRCUMSTANCES INFLUENCING stances of death may dictate a more elaborate INTERPRETATION protocol or suggest specific substances or groups of substances that should be assessed.1 Statistical parameters, such as "the lethal The only significance that routinely can be dose 50 percent" or "the lethal concentration attached to positive toxicologic findings is 50 percent," permit the determination of the that a detected substance is present. It is ex­ relative toxicity of a substance for various tremely rare that causal significance can be species or for subgroups within a single attributed to a substance on the basis of analy­ species. The relative toxicity of various sub­ tical data alone. More commonly, the results stances may be compared using these con­ of toxicologic findings must be interpreted cepts. They are, however, not applicable to with consideration given to investigations of single individuals within a population except the scene, activities of the decedent inunedi­ for approximation of the order of magnitude ately prior to death, first aid or treatment of susceptibility of the individual to the sub­ efforts provided by laymen or by medical stance under consideration. personnel, and long-term drug use history. When discussions of susceptibility are limited to single individuals, statistical con­ These investigations may result in the Cause of cepts lose validity. It becomes necessary to death being attributed to a su?stance which is examine the factors that influence variation in susceptibility of individuals within the The author acknowledges the support of the population. While many of these variables National Institute 011 Drug Abuse (grant #aH81 DA 01466·0 lSI) for part of the research underlying the have not 'been defined, some have been the discussion in this chapter. subject of investigation. Individual differences in susceptibility to 1For further discussion of topics treated here, see also chapter 3, "Postmortem Examination," and toxic substances are determined in part by chapter 5, "Forensic Toxicology in Death Investiga­ genetic factors. Differences in enzymatic tion." armamentaria which determine efficacy of 23 24 COMSTOCK detoxification are slow and fast acetylation, drug which would unequivocally be fatal for glucose-6-phosphate dehydrogenase deficien­ the phalmaC,)logically naive individual. cies, acetylcholinesterase deficiencies, and Interpretation of ihe toxicologic findings in metabolic correlates with the hemoglobin­ postmortem examination requires consider­ opathies, such as sickle cell disease. Defects ation of the genetic variable in susceptibility, in amino acid metabolism also may alter sus­ appraisal of preexisting pathology, and assess­ ceptibility to some toxic substances. The ment of the phalmacologic experience of the occurrence of these genetically determined decedent. variations in metabolism may place the indi­ vidual significantly outside the normal curve of susceptibility, influencing interpretation of TREATMENT PRIOR TO DEATH postmortem findings. An individual may be made more suscep­ The phrase "treatment prior to death" is tible to some substances by preexisting path­ used to describe occurrences during the inter­ ology. Susceptibility to carbon monoxide val between exposure and death. This includes may be increased by coexisting pathological first aid given by laymen as well as treat­ processes limiting exchange of oxygen in the ment administered by the medical community. lung or in a target organ, such as brain or Implicit is a survival interval between the heart. Acquired end-organ susceptibility is exposure and the occurrence of death. During illustrated by chronic exposure to anticholi­ this interval, the pharmacodynamics of redis­ nesterase insecticides. Reduction of choli­ tribution or disposition influence the interpre­ nesterase levels results in significant increase tation of the chemical findings at p0stmortem in response to administration of succinyl examination. choline. Impairment of liver function in­ Attempts at first aid may include the creases the relative susceptibility to sub­ mechanical induction of vomiting with conse­ stances dependent upon hepatic enzymes for quent aspiration asphyxia resulting in death detoxification. Significantly impaired renal unrelated to the concentration of toxic sub­ function increases susceptibility to sub­ stances present in the body. Efforts to induce stances normally excreted by the kidneY in a vomiting with sodium chloride are not un­ pharmacologically active form. common, and where vomiting has failed to Tolerance may develop to make an individ­ occur, death from hypernatrernia has occurred ual less susceptible to the lethal effects of in the presence of drugs of no toxicologic certain drugs. Dispositional tolerance is ex­ significance. Utilization of street treatment emplified by hepatic microsomal enzyme in­ folklore may result in intravenous injections duction. Experience with a toxic substance of milk or intravenous injections of table salt. over a period of time may result in increasing Other drugs that may be used in a treatment the rate of detoxification by increasing the effort include administration of ampheta­ activity of enzymes that effect the biotrans­ mines for barbiturate overdose and adminis­ formation of the substance to a nontoxic tration of chlorpromazine for amphetamine metabolite. Dispositional tolerance does not overdose. increase the concentration of toxic substance Once a patient finds his way to medical that can be tolerated at the target end organ. care, interpretation of subsequent postmortem Comparison of a tolerant individual with a findings may become very complicated. pharmacologically naive individual after a Administration of supportive care for pul­ similar survival interval shows lower tissue monary or cardiovascular failure may result concentrations of the substance in the toler­ in survival after the time that the original ant individual. "End-organ tolerance" des­ offending substance has been cleared from the cribes the adaptive procedure by which the body, with death due to injury incurred while target organ becomes less responsive to the the toxic substance was present. The per­ phalmacologic efhct of the substance. Devel­ formance of gastric lavage alters the interpre­ opment of end-organ tolerance permits an tation of postmortem examination of gastric individual to survive tissue concentrations of a contents and may add the complications of TREATMENT PRIOR TO DEATH AND POSTMORTEM TOXICOLOGIC FINDINGS 25 aspiration asphyxia or aspiration pneumonitis variety of complicating circumstances, any of of chemical or of infectious origin. In the which could be contributing factors in delayed treatment effort a variety of other drugs death. such as central nervous system and respiratory stimulants and pressor amines may be admin­ istered. Not only do these substances compli­ PHARMACODYNAMICS OF HOST­ cate interpretation of postmortem findings, SUBSTANCE RELATIONSHIPS but they may contribute to the lethality of the situation by adding the hazard of over­ Understanding the pharmacodynamics oc­ dose with these therapeutic agents. Other cm'ring with exposure to a toxic substance is possible complications that may occur during essential to interpretation of postmortem the treatment process include protracted findings. Figure 1 presents a schematic model hyperventilation; overcompensation of acid/ of the major ev~nts in absorption, redistribu­ base disturbances; dehydration and over­ tion, biotransformation, and excretion of· hydration in attempts at forced diuresis; toxic substances in the body. The substances obstruction of a main stem bronchus causing are absorbed through mucous membranes of collapse of the lung, arteriovenous shunting, the lung or the gastrointestinal tract i11to the and hypoxemia; and rupture of an emphyse­ systemic circulation. Water-soluble substances matous bleb with tension pneumothorax. may be excreted directly by the kidney. Monitoring of central venous pressure by way Lipid-soluble substances may be excreted by of a subclavian puncture has
Load more

Recommended publications
  • Quest Diagnostics Prescription Drug Monitoring Reference Guide
    Clinical Drug Monitoring Reference Guide Clinical Drug Monitoring Test List with Test Codes Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Alcohol Metabolites 90079 16910 92142 16217 Cocaine Metabolite 92225 70248 16888 90082 16916 Naltrexone 93753 Amphetamines 92222 70245 16885 70209 16913 Eszopiclone 91251 Opiates 92230 18991 16891 70237* 16298* Amphetamines Fentanyl 36278 36279 36280 18996 16900 Oxycodone 92231 18992 16892 70238 16920 91590 91589 92484 92483 with Reflex d/l Isomers Gabapentin 70205 16904 Phencyclidine 92232 18993 16893 90083 16921 Antidepressants (urine) 94032 Heroin Metabolite 92226 90081 16911 90333 90329 Pregabalin 70208 16908 Antidepressants (serum) 94031 Marijuana Metabolite 92227 18989 16889 70233 16917 Propoxyphene 92233 18995 16894 70239 16922 Antipsychotics (urine) 94528 MDMA/MDA 92228 90078 16909 90334 90331 Synthetic Cannabinoids 93027 Antipsychotics (serum) 94529 Meperidine 70206 16905 Synthetic Stimulants 90322 Barbiturates 92223 70246 16886 70230 16912 Methadone Metabolite 92229 18990 16890 70234 16918 Tapentadol 90244 90243 Benzodiazepines 92224 70247 16887 70231 16914 Methamphetamine Tramadol 70207 16906 90319 Buprenorphine 16207 70249 16901 18998 16213 d/l Isomers Tricyclic Antidepressants 70204 16903 Buprenorphine 93093 93094 Methylphenidate 90247 90246 with Naloxone Zolpidem 91258 Mitragynine 39241 39240 Carisoprodol 18999 16902 *Includes oxycodone drug class Test Profiles Profile Name Base Profile Profile 1 Profile 2 Profile 3 Profile 4 Profile 5 Profile 6
    [Show full text]
  • Emergency Medical Services Program Policies – Procedures – Protocols
    Emergency Medical Services Program Policies – Procedures – Protocols Protocols Table of Contents GENERAL PROVISIONS ................................................................................................ 3 DESTINATION DECISION SUMMARY-METRO BAKERSFIELD AREA ........................ 5 DETERMINATION OF DEATH ..................................................................................... 12 101 AIRWAY OBSTRUCTION ...................................................................................... 16 102 ALTERED LEVEL OF CONSCIOUSNESS ............................................................ 18 103 ALLERGIC REACTION/ANAPHYLAXIS ................................................................ 20 104 ASYSTOLE/ PULSELESS ELECTRICAL ACTIVITY ............................................. 22 105 BITES STINGS ENVENOMATION ......................................................................... 24 106 BRADYCARDIA ..................................................................................................... 26 107 BRIEF RESOLVED UNEXPLAINED EVENT ......................................................... 29 108 BURNS ................................................................................................................... 32 109 CHEMPACK ........................................................................................................... 35 110 CHEST PAIN OR ACUTE CORONARY SYNDROME ........................................... 37 111 CHEST TRAUMA ..................................................................................................
    [Show full text]
  • Highlights of This Issue
    THURSDAY, OCTOBER 4, 1973 WASHINGTON, D.C. HIGHLIGHTS OF THIS ISSUE This listing does not affect the legal status of any document published in this issue. Detailed table of contents appears inside. ECONOMIC STABILIZATION— CLC Phase IV pay and price regulations for certain reg­ istered, practical, and trained nurses (2 documents); effective 10—1—73....................... ........................ 27528, 27529 CLC allows Phase IV price increases for rubber tire and tube products; effective 10—8—73............................. ....... 27528 October 4, 1973— -Pages 27501-27574 METHAQUALONE— Justice Department classifies as Schedule II controlled substance; effective 10—4—73 27516 ARTISTS' PAINTS AND SUPPLIES— Consumer Product Safety Commission exempts from lead content restric­ tions; effective 12—3—73...-......... ........................................ 27514 DEFENSE CONTRACTS— Cost Amounting Standards Board extends disclosure statement filing requirements; effective 4— 1—74............................. ....................................... 27507 PUBLIC ASSISTANCE— HEW proposal on determin­ ing paternity of children receiving aid; comments by 1 1 -5 -7 3 ............................................ -. ............ : ........ 27530 SUGAR— USDA declares and reprorates 1973 quota deficits for Hawaii and Peru................... .................... ........................ 27509 USDA requires no proportionate shares for 1974 sugarbeet crop..--....................... ..............."...................... — 27510 PEANUTS— USDA proposes 1974
    [Show full text]
  • Drug Detection Time Window Chart
    Chesapeake Toxicology Resources Drug Detection Windows Updated as of December, 15th 2014 The length of time that the presence of drugs of abuse in the body can be detected is an important factor in drug screening. The chart below outlines approximate duration times. When interpreting the duration for the presence of drugs of abuse in the body, you must take into consideration variables including the body's metabolism, the subject's physical condition, overall body fluid balance, state of hydration and frequency of usage. Amphetamines Drug Name Metabolite Detection Window Prescription Names Amphetamine 3-5 Days Adderall, Adderall XR, Dexedrine, Spansule, DextroStat MDA 2-5 Days Tenamfetamine MDMA MDA 1-3 Days Adam, Ecstacy Methamphetamine Amphetamine 3-5 Days Desoxyn, Desoxyn Gradument Anti-epileptics Drug Name Metabolite Detection Window Prescription Names Gabapentin 1-5 Days Neurontin, Nupentin, Fanatrex, Gabarone, Gralise Pregablin 1-4 Days Lyrica CHESAPEAKE TOXICOLOGY RESOURCES- DRUG DETECTION TIMETABLE !1 Barbiturates Drug Name Metabolite Detection Window Prescription Names Amobarbital 2-10 Days Amytal, Amylobarbiton, Tuinal Butalbital 4-6 Days Axocet, Axotal, Bucet, Bupap, Butex Forte, Cephadyn, Dolgic, Esgic, Esgic-Plus, Fioricet, Fiorinal, Fiormor, Fiortal, Fortabs, Laniroif, Margesic, Marten-Tab, Medigesic, Phrenilin, Phrenilin Forte, Repan, Sedapap, Tencon, Triad Pentobarbital 2-10 Days Euthasol, Nembutal , Nembutal Sodium, Pentasol Phenobarbital Up to 16 days Antrocol, Barbidonna, Barbita, Bellacane, Bellatal, Bellergal-S, Chardonna-2,
    [Show full text]
  • Critical Care Nursing of Infants and Children Martha A
    University of Pennsylvania ScholarlyCommons Miscellaneous Papers Miscellaneous Papers 1-1-2001 Critical Care Nursing of Infants and Children Martha A. Q. Curley University of Pennsylvania, [email protected] Patricia A. Moloney-Harmon The Children's Hospital at Sinai Copyright by the author. Reprinted from Critical Care Nursing of Infants and Children, Martha A.Q. Curley and Patricia A. Moloney-Harmon (Editors), (Philadelphia: W.B. Saunders Co., 2001), 1,128 pages. NOTE: At the time of publication, the author, Martha Curley was affiliated with the Children's Hospital of Boston. Currently, she is a faculty member in the School of Nursing at the University of Pennsylvania. This paper is posted at ScholarlyCommons. http://repository.upenn.edu/miscellaneous_papers/4 For more information, please contact [email protected]. Please Note: The full version of this book and all of its chapters (below) can be found on ScholarlyCommons (from the University of Pennsylvania) at http://repository.upenn.edu/miscellaneous_papers/4/ Information page in ScholarlyCommons Full book front.pdf - Front Matter, Contributors, Forward, Preface, Acknowledgements, and Contents Chapter 1.pdf - The Essence of Pediatric Critical Care Nursing Chapter 2.pdf - Caring Practices: Providing Developmentally Supportive Care Chapter_3.pdf - Caring Practices: The Impact of the Critical Care Experience on the Family Chapter_4.pdf - Leadership in Pediatric Critical Care Chapter 5.pdf - Facilitation of Learning Chapter_6.pdf - Advocacy and Moral Agency: A Road Map for
    [Show full text]
  • Treatment Episode Data Set (TEDS) 2003 - 2013
    Treatment Episode Data Set (TEDS) 2003 - 2013 National Admissions to Substance Abuse Treatment Services DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration ACKNOWLEDGMENTS This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS), by Synectics for Management Decisions, Inc. (Synectics), Arlington, Virginia. Work by Synectics was performed under Task Order HHSS283200700048I/HHSS28342001T, Reference No. 283-07-4803 (Cathie Alderks, Task Order Officer). PUBLIC DOMAIN NOTICE All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, U.S. Department of Health and Human Services. RECOMMENDED CITATION Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-75, HHS Publication No. (SMA) 15-4934. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. ELECTRONIC ACCESS AND COPIES OF PUBLICATION This publication may be downloaded or ordered at store.samhsa.gov. Or call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). ORIGINATING OFFICE Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road, Room 2-1084 Rockville, Maryland 20857 December 2015 ii TABLE OF CONTENTS List of Tables ...................................................................................................................................v List of Figures ..............................................................................................................................
    [Show full text]
  • Barbiturate Blood Levels Found at Necropsy in Proven Cases of Acute Barbiturate Poisoning
    J. clin. Path., 1970, 23, 435-439 J Clin Pathol: first published as 10.1136/jcp.23.5.435 on 1 July 1970. Downloaded from Barbiturate blood levels found at necropsy in proven cases of acute barbiturate poisoning ROGER GILLETT AND FRANK G. WARBURTON From the Department ofPathology, Hope Hospital, Salford, Lancs SYNOPSIS In order to determine whether blood barbiturate levels could be used to ascertain that death had been caused by barbiturate overdose, samples of blood from 128 subjects of coroners' necropsies were examined for barbiturate content. Sixty of these were well authenti- cated cases of barbiturate overdosage, and barbiturates were implicated, together with other factors such as alcohol and carbon monoxide, in a further 16 cases. The remaining 52 cases were of an eliminatory nature, 10 of which had low barbiturate blood levels considered to be within the therapeutic range. The results indicate that when the accepted levels producing loss of consciousness are exceeded, and maintained, death will ensue if treatment is not given. These results may be of value in assessing findings in necropsies requested by the coroner, and are in no way applicable to the living patient in whom it is well established that recovery from higher blood levels http://jcp.bmj.com/ may take place if adequate treatment is available. Anatomical evidence of barbiturate poisoning but he notes that it must not be inferred that on September 23, 2021 by guest. Protected copyright. at necropsy is not specific, often amounting only finding these levels constitutes prima facie to signs of asphyxia. The presence of powder evidence of death from barbiturate poisoning.
    [Show full text]
  • A Comparison of Drug Use in Driver Fatalities and Similarly Exposed Drivers
    DOT HS-802 488 A COMPARISON OF DRUG USE IN DRIVER FATALITIES AND SIMILARLY EXPOSED DRIVERS Contract No. DOT-HS-4-00941 July 1977 Final Report PREPARED FOR: U.S. DEPARTMENT OF TRANSPORTATION NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION WASHINGTON, D.C. 20590 Document is available to the public through the National Technical Information Service, Springfield, Virginia 22161 This document is disseminated under the sponsorship of the Department of Transportation in the interest of information exchange. The United States Govern­ ment assumes no liability for its contents or use thereof. Technical Report Documentation Page 1. Report No. 2. Goeemm.nt Accession No. 3. Recipient's Catalog No. DOT HS-802 488 -^. 1. Title and Subtitle 5. Report Date July 1977 A COMPARISON OF DRU^ USE IN DRIVER FATALITIES 6. Performing Organization Code AND SIMILARLY EXPOSED DRIVERS . B. Performing Organization Report No. 7. Authorrs) Robert R. Blackburn, Edward J. Woodhouse 3963-D 9. Performing Organization Name and Address 10. Worb Unit No. (TRAIS) Midwest Research Institute I). Contract at Grant No. 425 Volker Boulevard DOT-HS-4-00941 Kansas City, Missouri 64110 13. Type of Report and Period Covered 12. Sponsoring Agency Name and Address 28 June 1974-25 March 1977 i U.S. Department of Transportation National Highway Traffic Safety Administration Final Report Washington, D.C. 20590 14. Sponsoring Agency Code 15. supplementary Notes 16. Abstract Crash information, urine, blood and bile samples from 900 fatally injured drivers were collected by medical examiners in 22 areas of the country. Ran­ domly selected living drivers were interviewed at times and places of recent fatal crashes in Dallas, Texas, and Memphis, Tennessee and breath, urine, and blood samples were obtained.
    [Show full text]
  • Clinical Toxicology J.A
    Postgrad Med J: first published as 10.1136/pgmj.69.807.19 on 1 January 1993. Downloaded from Postgrad Med J (1993) 69, 19 - 32 A) The Fellowship of Postgraduate Medicine, 1993 Reviews in Medicine Clinical toxicology J.A. Vale Director, National Poisons Information Service (Birmingham Centre), West Midlands Poisons Unit and Pesticide Monitoring Unit, Dudley Road Hospital, Birmingham B18 7QH, UK Introduction Selfpoisoning is the second most common cause of Much of the relevant literature relates to studies in acute medical presentation to hospital in the UK. volunteers given either a non-toxic marker or a However, as a result ofchanges over the last decade non-toxic dose ofa drug. As a result, the extrapola- both in the amount and type of agent ingested, the tion of many of these data to the poisoned patient majority of patients now suffer little if any adverse cannot be done with confidence. consequence and so require no active medical intervention. Nonetheless, a substantial minority Gastric lavage ofpoisoned patients do still require skilled medical management, often using the facilities of an inten- Although 'the idea of washing out the stomach sive care unit, if they are to survive without any with a syringe and tube, in cases where large important sequelae. Supportive therapy, including quantities oflaudanum and other poisons had been the correction of metabolic abnormalities, is of swallowed,' was first reported by Physick' in 1812 paramount importance in the care of such severely the value of gastric lavage remains controversial. by copyright. poisoned patients and this approach alone has Lavage performed 60 minutes after a therapeutic reduced the mortality significantly.
    [Show full text]
  • The Epidemiology of Benzodiazepine Misuse a Systematic Review
    Drug and Alcohol Dependence 200 (2019) 95–114 Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep Review The epidemiology of benzodiazepine misuse: A systematic review T ⁎ Victoria R. Votawa, , Rachel Geyerb, Maya M. Rieselbachc, R. Kathryn McHughb,d a Department of Psychology, University of New Mexico, MSC 03-2220, Albuquerque, NM, USA b Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA, USA c Department of Psychiatry, McLean Hospital, 115 Mill Street, Belmont, MA, USA d Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, USA ARTICLE INFO ABSTRACT Keywords: Background: Benzodiazepine misuse is a growing public health problem, with increases in benzodiazepine-re- Benzodiazepines lated overdose deaths and emergency room visits in recent years. However, relatively little attention has been Sedatives paid to this emergent problem. We systematically reviewed epidemiological studies on benzodiazepine misuse to Tranquilizers identify key findings, limitations, and future directions for research. Prescription drug misuse Methods: PubMed and PsychINFO databases were searched through February 2019 for peer-reviewed publica- Nonmedical prescription drug use tions on benzodiazepine misuse (e.g., use without a prescription; at a higher frequency or dose than prescribed). Eligibility criteria included human studies that focused on the prevalence, trends, correlates, motives, patterns, sources, and consequences of benzodiazepine misuse. Results: The search identified 1970 publications, and 351 articles were eligible for data extraction and inclusion. In 2017, benzodiazepines and other tranquilizers were the third most commonly misused illicit or prescription drug in the U.S. (approximately 2.2% of the population).
    [Show full text]
  • DRUGS of ABUSE I 2011 EDITION: a DEA Resource Guide of Actual Abuse of a Substance Is Indicative That a Drug Has a Schedule I Potential for Abuse
    U.S. Department of Justice DrUg enforcement AdminiStration WWW.DEA.GOV Drugs of2011 Abuse Edition A DEA REsouRcE GuiDE II. Controlled Substances Act coNtRolliNG DRuGs oR othER The Assistant Secretary, by authority of the Secretary, compiles substANcEs thRouGh FoRmAl the information and transmits back to the DEA: a medical and schEDuliNG scientific evaluation regarding the drug or other substance, a recommendation as to whether the drug should be controlled, The Controlled Substances Act (CSA) places all substances and in what schedule it should be placed. which were in some manner regulated under existing federal The medical and scientific evaluations are binding on the DEA law into one of five schedules. This placement is based upon with respect to scientific and medical matters and form a part the substance’s medical use, potential for abuse, and safety or of the scheduling decision. dependence liability. The Act also provides a mechanism for substances to be controlled (added to or transferred between Once the DEA has received the scientific and medical schedules) or decontrolled (removed from control). The evaluation from HHS, the Administrator will evaluate all available procedure for these actions is found in Section 201 of the data and make a final decision whether to propose that a drug Act (21 U.S.C. § 811). or other substance should be removed or controlled and into which schedule it should be placed. Proceedings to add, delete, or change the schedule of a drug If a drug does not have a potential for abuse, it cannot be or other substance may be initiated by the Drug Enforcement controlled.
    [Show full text]
  • Docobent Mune
    DOCOBENT MUNE ED 099 721 88 CO 009 311 Drug Information and Attitude Development: Interim Evaluation Report, August 1, 1972 to July 31, 1973, TISTITUTION Ferguson-Florissant School District, Ferguson, Bo. SPONS AGENCY Bureau of Elementary and Secondary Education (DBEV/OE), Washington, D.C. BUREAU NO 25-71-04-2 PUB DATE Sep 73 NOTE 284p. EDRS PRICE BF-80.75 BC-$13.80 PLUS POSTAGE DESCRIPTORS *Adolescents; Community Involvement; *Drug Education; Elementary Secondary Education; Family Involvement; *Inservice Education; *Program Descriptions; Research Projects IDENTIFIERS *Elementary Secondary Education Act Title III; ESEA Title III ABSTRACT This interim evaluation reports on the progress of an extensive drug education program in a St. Louis, Missouri school district. Designed to meet seven overall objectives, the project calls for comparisons between experimental and control groups at the elementary and secondary level. Far-reaching activities including staff orientation and training, curriculum developmentand implementation, staff and curriculum support, and parental involvement are discussed and evaluated in terms of their benefit to the overall objectives. A summary of all disseminationactivities is included, as are copies of all materials circulated by the project. Appendixes to the report include statistical analyses from both the student evaluation instruments and those utilized with the teacher training program. (Author/PC) DRUG INFORMATION 1 e n d ATTITUDE DEVELOPMENT U S DEPARTMENT OF ME Attic f DUCAT SON WELFARE NATIONAL INSTITUTE Of foutATioal 4415toocumfNT .445 SEENREPRO DuCED EYACTi Y AS RI. CEIV4 0 6 ROM 'He PE 66S066 OR 000AAtt A V 'ON GRsGIN AT try&T POuvts06 tiff ItS OR 04616410RIS SUMO DO NOT Alf cissAu61y REPEL SENT Off tCtAt tyAt0Aatil INSTITUTE Of Project Submitted Under EDUCAt Mfg Kiss 110,6OR POI Y Title III, ESEA Public Act 89-10 INTERIM EVALUATION REPORT Project # 25-71-04-2 Augrst 1, 1972 to July 31, 1973 RECrril=o The Ferguson-Florissant School District St.
    [Show full text]